With a market cap of over $200bn, Novartis is one of the largest pharmaceutical companies in the world and a leader in developing trusted innovative therapies to improve and prolong people’s lives. Under the visionary leadership of CEO Vas Narasimhan, Novartis has achieved extraordinary breakthroughs in gene, cell and other transformative therapies. Vas Narasimhan, discusses these key developments, and their implications with Magellan’s Chairman and Chief Investment Officer, Hamish Douglass.
